The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies (Q37209932)

19 August 2017

1 reference

title

The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies (English)

1 reference

19 August 2017

0 references

Tadeusz Robak

1 reference

19 August 2017

Piotr Smolewski

1 reference

19 August 2017

Pawel Robak

1 reference

19 August 2017

language of work or name

1 reference

1 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

19 August 2017

page(s)

1452-1462

1 reference

Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Prostaglandin synthase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Use of nonsteroidal antiinflammatory drugs and non-Hodgkin lymphoma: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Prescription medications associated with a decreased risk of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Non-hodgkin's lymphoma: Case control epidemiological study in Yorkshire

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Medication use and risk of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

International Commission for Protection against Environmental Mutagens and Carcinogens. An evaluation of the genetic toxicity of paracetamol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Regular analgesic use and risk of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Prescription drug use and risk of acute myeloid leukemia by French-American-British subtype: results from a Los Angeles County case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Opposing effects of aspirin and acetaminophen use on risk of adult acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Treatment of multiple myeloma with SDX-308.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Does low-dose aspirin have antineoplastic effects in multiple myeloma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Activation of the Wnt signaling pathway in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Cyclooxygenase isozymes are expressed in human myeloma cells but not involved in anti-proliferative effect of cyclooxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Cyclooxygenase-2 (Cox-2) and blast cells of patients with acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Cyclooxygenase-1, but not -2, is upregulated in NB4 leukemic cells and human primary promyelocytic blasts during differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Anti-inflammatory effects of indomethacin's methyl ester derivative and induction of apoptosis in HL-60 Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802108854

10.1080/10428190802108854

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference